剂量爬坡法治疗酪氨酸激酶抑制剂不耐受慢性粒细胞白血病一例并文献复习被引量：2

Dose escalating method in treatment of tyrosine kinase inhibitors intolerance chronic myeloid leukemia： report of one case and review of literature

原文传递

导出

摘要目的探讨酪氨酸激酶抑制剂（TKI）治疗慢性粒细胞白血病（CML）不耐受患者的临床特征和治疗方案.方法回顾性分析1例剂量爬坡法治疗TKI不耐受CML患者的临床资料,并复习相关文献.结果 TKI治疗CML不耐受患者,通过剂量爬坡法甲磺酸伊马替尼小剂量开始逐渐加量治疗可耐受.结论剂量爬坡法治疗TKI不耐受CML患者有效且无明显血液学不良反应.

作者马利吴涛汉英贾占武郭娟娟白海王存邦

机构地区兰州军区兰州总医院血液科

出处《白血病．淋巴瘤》 CAS 2018年第2期123-126,共4页 Journal of Leukemia & Lymphoma

基金甘肃省自然科学基金（145RJZA151）

关键词白血病髓系慢性剂量爬坡法酪氨酸激酶抑制剂甲磺酸伊马替尼达沙替尼

分类号 R733.72 [医药卫生—肿瘤]

引文网络
相关文献

参考文献12

1刘文玲,冀林华,李占全,崔森,耿慧.达沙替尼与伊马替尼治疗慢性粒细胞白血病慢性期患者效果的Meta分析[J].白血病．淋巴瘤,2016,25(4):228-233. 被引量：5
2王娟,高松坤,李珍,李梦娟,张类莉,宋永平.慢性粒细胞白血病435例甲磺酸伊马替尼治疗后血液学不良反应[J].白血病．淋巴瘤,2015,24(8):479-482. 被引量：5
3江倩,刘正琛,张颂昕.中国慢性髓性白血病患者酪氨酸激酶抑制剂治疗现状的调研：从患者的角度[J].中华血液学杂志,2016,37(7):559-564. 被引量：10
4陈英玉,胡建达.酪氨酸激酶抑制剂治疗中停药问题及根除慢性髓系白血病干细胞的治疗选择：第55届美国血液学会年会报道[J].白血病．淋巴瘤,2014,23(1):12-16. 被引量：4
5杨晨敏,李健.以黄疸、肝大起病的慢性粒细胞白血病一例并文献复习[J].白血病．淋巴瘤,2014,23(1):55-57. 被引量：2
6冯雅青,刘喜,赵芳,张利东,张艳芳,马建华.达沙替尼治疗慢性粒细胞白血病急变为急性淋巴细胞白血病合并中枢神经系统白血病一例并文献复习[J].肿瘤研究与临床,2016,28(2):121-123. 被引量：6
7于露,汪海波,江倩.中国慢性髓性白血病慢性期患者报告的酪氨酸激酶抑制相关不良反应及其对日常生活的影响研究[J].中华血液学杂志,2016,37(11):929-935. 被引量：7
8陈彭(综述),胥灵敏,刘利(审校).慢性粒细胞白血病的发病机制及治疗现状[J].白血病．淋巴瘤,2016,25(8):509-512. 被引量：6
9于露,汪海波,黄晓军,江倩.格列卫相关不良反应对中国慢性髓性白血病患者日常生活影响的研究[J].中华血液学杂志,2016,37(7):554-558. 被引量：9
10张博,江浩,路瑾.第361例贫血-慢性粒细胞白血病-酪氨酸激酶抑制剂治疗不恢复-多发性骨髓瘤[J].中华医学杂志,2016,96(8):660-662. 被引量：3

二级参考文献198

1王吉刚,张海婷,周凡,刘彦琴,白颖,刘景华,李敏燕.慢性髓细胞白血病患者骨髓基质细胞与K562细胞共培养对伊马替尼耐药的影响[J].中国组织工程研究,2015,19(6):849-853. 被引量：2
2江倩,陈珊珊,江滨,江浩,丘镜滢,刘艳荣,张艳,秦亚溱,陆颖,黄晓军,陆道培.甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期100例追踪观察[J].中华血液学杂志,2006,27(11):721-726. 被引量：39
3Sweet K, Oehler. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?[C]//. Hematology Am Soc Hematol Educ Program 2013, New Orleans: ASH Annual Meeting, 2013: 184-188.
4Mahon FX, Rea D, Guilhot J, et at. Discontinuation ofimatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, muhicentre Stop Imatinib (STIM) trial[J]. Lancet Oncol, 2010, 11 : 1029-1035.
5Mahon FX, Rea D, Guilhot J, et at. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: updated results of the STIM study [abstract] [J]. Blood (ASH Annual Meeting Abstracts), 2011, 118: 603.
6Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study[J]. Blood, 2013, 122: 515-522.
7Mahon FX, Nicolini F, Noel MP, et at. Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib[J]. Blood (ASH Annual Meeting Abstract), 2013, 122: 654.
8Rea D, Dulphy N, Henry G, et at. Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)-ehronic myeloid leukemia (CML) with undetectable bcr-abl transcripts for at least 2 years: preliminary results from immunostim, on behalf of STIM investigators[J]. Blood (ASH Annual Meeting Abstract), 2013, 122: 856.
9Sirard C, Lapidot T, Vormoor J, et al. Normal and leukemic SCID- repopulating cells (SRC) c：xist in the bone marrowand peripheral blood from CML patients in chronic phase,whereas leukemic SRC are detected in blast crisis[J]. Blood, 1996, 87:1539-1548.
10Jamieson CHM, Ailles LE, Dylla S J, et at. Granulocytemacrophage progenitors as candidate leukemic stem ceils in blast-crisis CML[J]. N Engl J Med, 2004, 351: 657-667.